Form 4: Lexeo CTO Sells Shares for Tax Obligations

Lexeo Therapeutics' Chief Technical Officer, Jose Manuel Otero, sold 721 shares of common stock at a weighted average price of $9.27 to cover tax obligations related to restricted stock units.

Summary

• Jose Manuel Otero, Chief Technical Officer of Lexeo Therapeutics, Inc. (LXEO), reported a sale of common stock.
• The transaction involved the disposition of 721 shares of LXEO common stock on August 18, 2025.
• The shares were sold at a weighted average price of $9.27 per share, with individual trades ranging from $9.09 to $9.37.
• The sale was conducted to cover tax obligations arising from the release of restricted stock units (RSUs).
• Following this transaction, Otero beneficially owns 63,476 shares of common stock, which includes 47,733 RSUs.

Sentiment

Score: 5

Explanation: Neutral. The transaction is a routine insider sale to cover tax obligations, which is a common event and does not typically reflect a change in management's confidence or the company's prospects.

Positives

• The sale was explicitly stated to cover tax obligations, indicating a non-discretionary reason rather than a lack of confidence in the company's future.

Negatives

• A reduction in direct beneficial ownership by a key executive, even if for tax purposes, slightly decreases insider alignment.

Future Outlook

NA

Management Comments

• The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Industry Context

This Form 4 filing reports a routine insider transaction, detailing an executive's stock activity. It does not provide information directly related to broader industry trends, competitive landscape, or Lexeo Therapeutics' operational performance within the biotechnology sector.

Stakeholder Impact

• Shareholders: The impact on shareholders is generally neutral. While there is a minor reduction in direct insider ownership, the stated reason for the sale (tax obligations) suggests it is not indicative of a lack of confidence in the company's future performance.

Key Dates

Recommendation

The reported transaction is a routine sale by an executive to cover tax liabilities associated with the vesting of restricted stock units. This is a common occurrence and does not typically signal a change in the company's fundamentals or management's long-term outlook. Therefore, it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Lexeo Therapeutics, LXEO, Jose Manuel Otero, Chief Technical Officer, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, Tax Obligations, Biotechnology, Pharmaceuticals